Related articles
-
NewsSymptoms of long-COVID can last up to two years after infection with COVID-19
According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. In more than half of them the symptoms persisted for two years.
-
NewsTecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovrimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial.
-
NewsDrug may prevent COVID-19 in exposed people within households, major trial finds
An international clinical trial of the oral antiviral drug, ensitrelvir, which has been proved to prevent COVID-19 cases, was conducted and found to be very effective. The drug will be awaiting for approval before becoming widely available.
More from News
-
NewsNew automated method increases the efficiency of bioactive natural product discovery
In light of the technological advancement in machine learning and bioinformatics tools, researchers developed a fully-automated and integrated platform that enables them to easily identify bioactive natural products in Streptomyces.
-
NewsPromising new research shows potential to cure recurrent urinary tract infectionsed
Researchers examine the effectiveness of nanogel as a drug delivery system to direct antibiotics into targeted infected cells to improve UTI treatment.
-
NewsUltra-low dose CT aids pneumonia diagnosis in immunocompromised patients
Denoised ultra-low dose CT can effectively diagnose pneumonia in immunocompromised patients using only 2% of the radiation dose of standard CT, according to a study.
No comments yet